Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung CancerShun Lü, Xiaosheng Hang, Guohua Yu et al.|JAMA|2024Cited by 359
The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer—A Phase II StudyWenqun Xing, Quanli Gao, Lingdi Zhao et al.|Frontiers in Immunology|2021Cited by 73
Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b TrialWanpu Yan, Yi‐Long Wu, Wen‐Zhao Zhong et al.|Journal of Thoracic Oncology|2022Cited by 34
The sequence of chemotherapy and anti-PD-1 antibody influence the efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell cancer: A phase II study.Lingdi Zhao, Quanli Gao, Wenqun Xing et al.|Journal of Clinical Oncology|2021Cited by 15
366 A randomized double-blind placebo-controlled phase III study evaluating perioperative toripalimab combined with platinum-based doublet chemotherapy in resectable stage III NSCLCWenxiang Wang, Tao Xu, Lin Wu et al.|Regular and Young Investigator Award Abstracts|2020Cited by 2